Current HIV/AIDS Reports

, Volume 1, Issue 2, pp 82–88 | Cite as

New antiretroviral agents for the treatment of HIV infection

  • Kristen Marks
  • Roy M. Gulick
Article

Abstract

Issues, such as complexity, tolerability, and drug resistance and cross-resistance, limit the effectiveness of current antiretroviral regimens and make the continued development of newer agents important, despite the availability of 20 approved drugs for the treatment of HIV infection. Many new compounds are in development in existing classes: nucleoside and nucleotide analogue reverse transcriptase inhibitors (eg, D-d4FC and SPD754), non-nucleoside analogue reverse transcriptase inhibitors (eg, capravirine and TMC125), and protease inhibitors (eg, tipranavir and TMC114). In addition, newer classes of antiretroviral drugs, such as HIV entry inhibitors (eg, TNX-355, SCH 417690, UK-427,857, AMD 11070), that target the first step in the HIV life cycle are under development. Continued improvement in the treatment of HIV infection will result from the availability of convenient, well-tolerated, and affordable drugs with potent and durable antiretroviral activity.

Keywords

Ritonavir Tipranavir 43rd Interscience Capravirine Nucleotide Analogue Reverse Transcriptase Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Geleziunas R, Gallagher K, Zhang H, et al.: HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2’,3’-dideoxy-2’,3’-didehydro-5-fluorocytidine (Reverset). Antivir Chem Chemother 2003, 14:49–59.PubMedGoogle Scholar
  2. 2.
    Murphy RL, Schürmann D, Kravec I, et al.: Pharmacokinetics, safety and antiviral activity of the nucleoside Reverset following single doses in HIV-1 infected patients [abstract]. Paper presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France; July 13–16, 2003.Google Scholar
  3. 3.
    Murphy RL, Schürmann D, Beard A, et al.: Tolerance and potent anti-HIV-1 activity of Reverset following 10 days of mono-therapy in treatment-naïve individuals [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.Google Scholar
  4. 4.
    Locas C, Ching S, Damment S: Safety profile of SPD754 in Cynomolgus monkeys treated for 52 weeks [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.Google Scholar
  5. 5.
    Francis RJ, Lanclos L, Shiveley L, Sawyer J: Pharmacokinetics of SPD754, a new cytidine analogue in healthy volunteers [abstract]. Paper presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France; July 13–16, 2003.Google Scholar
  6. 6.
    Cahn P, Lange J, Cassetti I, et al.: Anti-HIV-1 activity of SPD754, a new NRTI: results of a 10 day monotherapy study in treatment-naive HIV patients [abstract]. Paper presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France; July 13–16, 2003.Google Scholar
  7. 7.
    Collins P, Shiveley L, Anderson C, Bethell R: Analysis of the genotypes of viruses isolated from patients after 10 days monotherapy with SPD754 [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.Google Scholar
  8. 8.
    Bethell R, Adams J, De Muys J, et al.: Pharmacological evaluation of a dual deoxycytidine analogue combination: 3TC and SPD754 [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.Google Scholar
  9. 9.
    Fujiwara T, Sato A, El-Farrash M, et al.: S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1998, 42:1340–1345.PubMedGoogle Scholar
  10. 10.
    Hayashi S, Amantea M, Hawley P, et al.: Effects of fasting (F), high fat (H) and low fat (L) meals on the pharmacokinetics (PK) of a single oral dose of capravirine (CPV), a nonnucleoside reverse transcriptase inhibitor (NNRTI), in healthy volunteers [abstract]. Paper presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada; September 17–20, 2000.Google Scholar
  11. 11.
    Jacobs M, Leoung G, Dezube B, et al.: Pharmacokinetic (PK) interaction of AG1549, a novel nonnucleoside reverse transcriptase inhibitor (NNRTI), with protease inhibitors (PI) [abstract]. Paper presented at the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; January 30–February 2, 2000.Google Scholar
  12. 12.
    Amantea MA, Raber S, Reynolds R, et al.: Pharmacokinetic drug-drug interaction between capravirine, lopinavir/ ritonavir and tenofovir in healthy volunteers [abstract]. Paper presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 14–17, 2003.Google Scholar
  13. 13.
    Dezube BJ, Jacobs MS, Leoung G, et al.: A second-generation non-nucleoside reverse transcriptase inhibitor (S-1153) for the treatment of HIV-1 infection: a phase I study [abstract]. Paper presented at the 12th World AIDS Conference. Geneva, Switzerland; June 28–July 3, 1998.Google Scholar
  14. 14.
    Hernandez J, Amdador L, Amantea M, et al.: Short-course monotherapy with AG1549, a novel nonnucleoside reverse transcriptase inhibitor (NNRTI) in antiretroviral-naïve patients [abstract]. Paper presented at the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; January 30-February 2, 2000.Google Scholar
  15. 15.
    Wolfe P, Hawley P, Boccia G, et al.: Safety and efficacy of capravirine versus placebo in HIV-infected patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen: results of a phase II, double-blind, placebocontrolled study [abstract]. Paper presented at the 8th Annual Conference on Retroviruses and Opportunistic Infections. Chicago, IL; February 4–8, 2000.Google Scholar
  16. 16.
    Hammond JL, Amantea M, Raber S, et al.: Long-term virological response to capravirine in HIV-infected NNRTIexperienced patients [abstract]. Paper presented in the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 14–17, 2003.Google Scholar
  17. 17.
    Ludovici DW, De Corte BL, Kukla MJ, et al.: Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues. Bioorg Med Chem Lett 2001, 11:2235–2239.PubMedCrossRefGoogle Scholar
  18. 18.
    Gruzdev B, Rakhmanova A, Doubovskaya E, et al.: A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS 2003, 17:2487–2494.PubMedCrossRefGoogle Scholar
  19. 19.
    Gazzard BG, Pozniak AL, Rosenbaum W, et al.: An open-label assessment of TMC125, a new next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 2003, 17:F49-F54. A short-term study demonstrating the virologic activity of TMC125 in NNRTI-experienced patients.Google Scholar
  20. 20.
    Larder BA, Hertogs K, Bloor S, et al.: Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000, 14:1943–1948.PubMedCrossRefGoogle Scholar
  21. 21.
    Cooper D, Hall D, Jayaweera D, et al.: Baseline phenotypic susceptibility to tipranavir/ritonavir (TPV/r) is retained in isolates from patients with multiple-protease inhibitor (PI-experience) (BI 1182-52) [abstract]. Paper presented at the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 24–28, 2003.Google Scholar
  22. 22.
    McCallister S, Sabo J, Galitz L, Mayers D: An open-label steady state investigation of the pharmacokinetics (PK) of tipranavir (TPV) and ritonavir (RTV) and their effects on cytochrome P-450 (3A4) activity in normal healthy volunteers (BI 1182.5) [abstract]. Paper presented at the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA; February 24–28, 2002.Google Scholar
  23. 23.
    Wang Y, Daenzer C, Wood R, et al.: The safety, efficacy and viral dynamics analysis of tipranavir, a new-generation protease inhibitor, in a phase II study in antiretroviral-naive HIV-1-infected patients [abstract]. Paper presented at the 7th Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; January 30–February 2, 2000.Google Scholar
  24. 24.
    Slater L, Farthing C, Jayaweera J, et al.: Safety and efficacy of tipranavir, a novel non-peptidic protease inhibitor (PI), plus ritonavir in PI-failure patients [abstract]. Paper presented at the 41st Interscience Conference on Antimicrobial and Antiviral Chemotherapy. Chicago, IL; December 16–19, 2001.Google Scholar
  25. 25.
    Curry R, Markowitz M, Slater L, et al.: Safety and efficacy of tipranavir, a non-peptidic protease inhibitor, in multiple failure patients (BI 1182.2) [abstract]. Paper presented at the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina; July 8–11, 2001.Google Scholar
  26. 26.
    Gathe J, Kohlbrenner VM, Pierone G, et al.: Tipranavir/ ritonavir demonstrates potent efficacy in multiple protease inhibitor experienced patients: BI 1182.52 [abstract]. Paper presented at the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 24–28, 2003. A clinical study demonstrating the antiretroviral activity of tipranavir in PI-experienced patients.Google Scholar
  27. 27.
    Squires K, McCallister S, Lazzarin A, et al.: Tipranavir/ritonavir demonstrates a robust resistance profile in multiple protease inhibitor-experienced patients: correlation of baseline genotype and antiviral activity in BI 1182.52 [abstract]. Paper presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France; July 13–16, 2003.Google Scholar
  28. 28.
    De Meyer S, Van Marck H, Van Den Bulcke T, et al.: Phenotypic and genotypic profiling of TMC114, a potent next-generation PI, against some 1600 recent PI-resistant clinical isolates [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infection. San Francisco, CA; February 8–11, 2004.Google Scholar
  29. 29.
    Van der Geest R, Van der Sandt, Gille D, et al.: Safety, tolerability and pharmacokinetics of escalating single oral doses of TMC114, a novel protease inhibitor (PI) highly active against HIV-1 variants resistant to other PIs [abstract]. Paper presented at the 41st Interscience Conference on Antimicrobial and Antiviral Chemotherapy. Chicago, IL; December 16–19, 2001.Google Scholar
  30. 30.
    Arasteh K, Clumecket N, Pozniak A, et al.: Antiretroviral activity, safety and pharmacokinetics of TMC114, a nextgeneration HIV-1 protease inhibitor in multiple PI-experienced patients [abstract]. Paper presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France; July 13–16, 2003.Google Scholar
  31. 31.
    Peeters M, Van Baelen B, De Meyer S, et al.: TMC114/RTV activity in multiple PI-experienced patients: correlation of baseline genotype, phenotype, pharmacokinetics, and IQ with antiviral activity at day 14 [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco; CA; February 8–11, 2004.Google Scholar
  32. 32.
    Moore JP, Sattentau GQ, Klasse PJ, Burkly LC: A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformation changes to the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J Virol 1992, 66:4784–4793.PubMedGoogle Scholar
  33. 33.
    Reimann KA, Khunkhun R, Lin W, et al.: A humanized, nondepleting anti-CD4 antibody that blocks virus entry inhibits virus replication in rhesus monkey chronically infected with simian immunodeficiency virus. AIDS Res Hum Retroviruses 2002, 18:747–755.PubMedCrossRefGoogle Scholar
  34. 34.
    Reimann K, Liin W, Bixler S, et al.: A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res Hum Retroviruses 1997, 13:933–943.PubMedCrossRefGoogle Scholar
  35. 35.
    Boon L, Holland B, Gordon W, et al.: Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates. Toxicology 2002, 172:191–203.PubMedCrossRefGoogle Scholar
  36. 36.
    Kuritzkes DR, Jacobson J, Powderly WG, et al.: Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004, 189:286–291. Proof-of-concept that a CD4 attachment inhibitor demonstrates antiretroviral activity in individuals with HIV.PubMedCrossRefGoogle Scholar
  37. 37.
    Jacobson JM, Kuritzkes DR, Godofsky E, et al.: Phase Ib study of the anti-CD4 monoclonal antibody TNX-355 in HIV-1-infected subjects: safety and antiretroviral activity of multiple doses [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.Google Scholar
  38. 38.
    Baroudy B: Co-receptor inhibitors [abstract]. Paper presented at the XIV International AIDS Conference. Barcelona, Spain; July 7–12, 2002.Google Scholar
  39. 39.
    Schurmann D, Rouzier R, Nougarede R, et al.: SCH D: antiviral activity of a CCR5 receptor antagonist [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.Google Scholar
  40. 40.
    Macartney MJ, Dorr PK, Smith-Burchnell C, et al.: In vitro antiviral profile of UK-427,857: a novel CCR5 antagonist [abstract]. Paper presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 14–17, 2003.Google Scholar
  41. 41.
    Russell D, Bakhtyari A, Jazrawi RP, et al.: Multiple dose study to investigate the safety of UK-427,857 (100 mg or 300 mg) BID for 28 days in healthy males and females [abstract]. Paper presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 14–17, 2003.Google Scholar
  42. 42.
    Pozniak AL, Fatkenheuer G, Johnson M, et al.: Effect of shortterm monotherapy with UK-427,857 on viral load in HIVinfected patients [abstract]. Paper presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 14–17, 2003.Google Scholar
  43. 43.
    Westby M, Whitcomb J, Huang W, et al.: Reversible predominance of CXCR4 utilizing variants in a non-responsive dual tropic patient receiving the CCR5 antagonist UK-427,857 [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.Google Scholar
  44. 44.
    Schols D, Claes S, De Clercq E, et al.: AMD-3100, a CXCR4 antagonist, reduced HIV viral load and X4 virus levels in humans [abstract]. Paper presented at the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA; February 24–28, 2002.Google Scholar
  45. 45.
    Hendrix C, Collier AC, Lederman M, et al.: AMD-3100 CXCR4 receptor blocker fails to reduce HIV viral load by > 1 log following 10-day continuous infusion [abstract]. Paper presented at the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA; February 24–28, 2002.Google Scholar
  46. 46.
    Schols D, Vermeire K, Hatse S, et al.: In vitro anti-HIV activity profile of AMD 887, a novel CCR5 antagonist, in combination with the CXCR4 inhibitor AMD 070 [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.Google Scholar

Copyright information

© Current Science Inc. 2004

Authors and Affiliations

  • Kristen Marks
  • Roy M. Gulick
    • 1
  1. 1.Cornell Clinical Trials UnitWeill Medical College of Cornell UniversityNew YorkUSA

Personalised recommendations